Study summary

An inhaled kinase inhibitor fell short in phase 3

PROSERA trial (seralutinib) · 390 people, phase 3 · Topline results February 2026

What was tested

Seralutinib, an inhaled drug blocking PDGF and other growth signals in the lung vessels, against placebo, for pulmonary arterial hypertension.

What they found

• Did not meet its prespecified primary efficacy threshold on 6-minute walk distance, despite nominal statistical significance.
• The sponsor paused enrollment in another seralutinib study.

What it means

A setback for inhaled anti-remodeling drugs, though the approach remains under study.